Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7910716 | 0.95 | AGTR1 (0.54) | AGTR1AGTR2 | |
| SCHEMBL9387341 | 0.95 | AGTR1 (0.59) | AGTR1AGTR2 | |
| SCHEMBL669267 | 0.91 | AGTR1 (0.58) | AGTR1AGTR2 | |
| SCHEMBL9427022 | 0.90 | AGTR1 (0.57) | AGTR1AGTR2 | |
| SCHEMBL7911064 | 0.90 | AGTR1 (0.47) | AGTR1AGTR2 | |
| SCHEMBL668340 | 0.90 | AGTR1 (0.48) | AGTR1AGTR2 | |
| SCHEMBL7310985 | 0.90 | AGTR1 (0.61) | AGTR1AGTR2 | |
| SCHEMBL3844504 | 0.89 | AGTR1 (0.46) | AGTR1AGTR2 | |
| SCHEMBL12991354 | 0.88 | AGTR2 (0.56) | AGTR1AGTR2 | |
| SCHEMBL7428535 | 0.87 | AGTR1 (0.46) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | OSAKA UNIVERSITY (JP) | 2012-11-29 | — | — | US | claimed |
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | claimed |
| EP-2174666-A1 | MEDICINAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE | Daiichi Sankyo Company, Limited (JP) | 2010-04-14 | — | — | EP | claimed |
| EP-1884240-B1 | PHARMACEUTICAL FOR PREVENTION OR TREATMENT OF BONE METABOLIC DISEASE | DAIICHI SANKYO CO LTD (JP) | 2009-11-11 | — | — | EP | claimed |
| US-20090082411-A1 | Pharmaceutical for prevention or treatment of bone metabolic disease | DAIICHI SANKYO COMPANY, LIMITED (75% INTEREST) (JP) | 2009-03-26 | — | — | US | claimed |
| EP-1884240-A1 | PHARMACEUTICAL FOR PREVENTION OR TREATMENT OF BONE METABOLIC DISEASE | Daiichi Sankyo Company, Limited (JP) | 2008-02-06 | — | — | EP | claimed |
| EP-0545912-B1 | 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-04-25 | — | — | EP | claimed |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | OSAKA UNIVERSITY (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20120046327-A1 | METHOD FOR INHIBITING THE INDUCTION AND FORMATION OF OSTEOCLASTS | OSAKA UNIVERSITY (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2174666-A1 | MEDICINAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE | Daiichi Sankyo Company, Limited (JP) | 2010-04-14 | — | — | EP | disclosed |
| EP-1884240-B1 | PHARMACEUTICAL FOR PREVENTION OR TREATMENT OF BONE METABOLIC DISEASE | DAIICHI SANKYO CO LTD (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20090082411-A1 | Pharmaceutical for prevention or treatment of bone metabolic disease | DAIICHI SANKYO COMPANY, LIMITED (75% INTEREST) (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1884240-A1 | PHARMACEUTICAL FOR PREVENTION OR TREATMENT OF BONE METABOLIC DISEASE | Daiichi Sankyo Company, Limited (JP) | 2008-02-06 | — | — | EP | disclosed |
| EP-0545912-B1 | 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-04-25 | — | — | EP | disclosed |
| US-5646171-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-07-08 | — | — | US | disclosed |
| US-5616599-A | HYPOTENSIVE AGENTS FOR CARDIOVASCULAR DISORDER | SANKYO COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | disclosed |
| EP-0545912-A2 | 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1993-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130567-A1 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE | AGTR1, AGTR2, ACE | AGTR1 1/4885AGTR2 2/4885 |
| US-20120046327-A1 | METHOD FOR INHIBITING THE INDUCTION AND FORMATION OF OSTEOCLASTS | SOST, CD14, MYD88 | AGTR1 35/4885AGTR2 64/4885 |
| US-20120302614-A1 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER | AGTR2, AGTR1, BDKRB2 | AGTR1 2/4885AGTR2 1/4885 |
| US-20090082411-A1 | Pharmaceutical for prevention or treatment of bone metabolic disease | AGTR1, AGTR2, MC2R | AGTR1 1/4885AGTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.